Is Sanara Medtech Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: SMTI) stock is to Strong Buy SMTI stock.
Out of 1 analyst, 1 (100%) are recommending SMTI as a Strong Buy, 0 (0%) are recommending SMTI as a Buy, 0 (0%) are recommending SMTI as a Hold, 0 (0%) are recommending SMTI as a Sell, and 0 (0%) are recommending SMTI as a Strong Sell.
What is SMTI's earnings growth forecast for 2024-2024?
(NASDAQ: SMTI) Sanara Medtech's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Sanara Medtech's earnings in 2024 is -$6,565,762.
In 2024, SMTI is forecast to generate -$17,756,361 in earnings, with the lowest earnings forecast at -$17,756,361 and the highest earnings forecast at -$17,756,361.
What is SMTI's forecast return on equity (ROE) for 2024-2024?
(NASDAQ: SMTI) forecast ROE is -42.57%, which is considered weak.
What is SMTI's Price Target?
According to 1 Wall Street analyst that have issued a 1 year SMTI price target, the average SMTI price target is $44.00, with the highest SMTI stock price forecast at $44.00 and the lowest SMTI stock price forecast at $44.00.
The Wall Street analyst predicted that Sanara Medtech's share price could reach $44.00 by May 15, 2025. The average Sanara Medtech stock price prediction forecasts a potential upside of 47.65% from the current SMTI share price of $29.80.
What is SMTI's Earnings Per Share (EPS) forecast for 2024-2024?
(NASDAQ: SMTI) Sanara Medtech's current Earnings Per Share (EPS) is -$0.78. In 2024, SMTI's EPS is forecast to hit -$2.03 (min: -$2.03, max: -$2.03).
What is SMTI's forecast return on assets (ROA) for 2024-2024?
(NASDAQ: SMTI) forecast ROA is -24.2%, which is lower than the forecast US Medical Instruments & Supplies industry average of 8.67%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.